Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial*

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Critical Care Medicine

• Publication date

  2004-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.CCM.0000108867.87890.6DPMID 14758145
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High-Dose Antithrombin III for Severe Sepsis?

  2006cited by this paper
• Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial.

  2003influential reference
• The pathophysiology and treatment of sepsis.

  2003cited by this paper
• Joseph

  2002cited by this paper
• The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis

  2002influential reference
• Regulation of Toll-Like Receptor 4 Expression in the Lung Following Hemorrhagic Shock and Lipopolysaccharide1

  2002cited by this paper
• The Role of Platelet-Activating Factor in Sepsis: A Bench-to-Bedside Review

  2002cited by this paper
• Activated platelets mediate inflammatory signaling by regulated interleukin 1β synthesis

  2001cited by this paper
• High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial

  2001cited by this paper
• Toll-Like Receptor-4 Is Expressed by Macrophages in Murine and Human Lipid-Rich Atherosclerotic Plaques and Upregulated by Oxidized LDL

  2001cited by this paper
• Oxidized Low Density Lipoprotein Exposure Alters the Transcriptional Response of Macrophages to Inflammatory Stimulus*

  2001cited by this paper
• Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.

  2001cited by this paper
• Platelet-activating factor and related lipid mediators.

  2000cited by this paper
• Phase II multicenter clinical study of the platelet‐activating factor receptor antagonist BB‐882 in the treatment of sepsis

  2000cited by this paper
• Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group.

  2000cited by this paper
• Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: Time for a reevaluation

  2000cited by this paper
• Bioactive phospholipid oxidation products.

  2000cited by this paper
• Clinical trials for severe sepsis. Past failures, and future hopes.

  1999cited by this paper
• Two of the usual suspects, platelet-activating factor and its receptor, implicated in acute lung injury.

  1999cited by this paper
• Expression of Plasma Platelet-activating Factor Acetylhydrolase Is Transcriptionally Regulated by Mediators of Inflammation*

  1998cited by this paper
• THE CLEVELAND CLINIC FOUNDATION

  1998cited by this paper
• Effect of recombinant platelet-activating factor acetylhydrolase on two models of experimental acute pancreatitis.

  1998cited by this paper
• Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group.

  1998cited by this paper
• A juxtacrine mechanism for neutrophil adhesion on platelets involves platelet-activating factor and a selectin-dependent activation process.

  1998cited by this paper
• The sirens' songs of confirmatory sepsis trials: selection bias and sampling error.

  1998cited by this paper
• PLATELET‐ACTIVATING FACTOR (PAF) IN EXPERIMENTAL AND CLINICAL SEPSIS

  1997cited by this paper
• Platelet-activating Factor Acetylhydrolases*

  1997cited by this paper
• REDUCED PAF‐ACETYLHYDROLASE ACTIVITY IS ASSOCIATED WITH POSTINJURY MULTIPLE ORGAN FAILURE

  1997cited by this paper
• Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet‐activating factor receptor

  1997cited by this paper
• Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

  1997cited by this paper
• Anti-inflammatory properties of a platelet-activating factor acetylhydrolase

  1995cited by this paper
• Rush-Presbyterian-St. Luke's Medical Center and Others v. Hellenic Republic and Others

  1995cited by this paper
• Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome.

  1995cited by this paper
• Platelet-activating factor mediates procoagulant activity on the surface of endothelial cells by promoting leukocyte adhesion.

  1995cited by this paper
• Platelet‐activating factor: a mediator for clinicians

  1995cited by this paper
• P-selectin and platelet-activating factor mediate initial endotoxin- induced neutropenia

  1994cited by this paper
• The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination.

  1994cited by this paper
• Plasma degradation of platelet‐activating factor in severely ill patients with clinical sepsis

  1994cited by this paper
• Platelet-activating factor may stimulate both receptor-dependent and receptor-independent increases in [Ca2+] in human airway epithelial cells.

  1994cited by this paper
• The metabolic effects of platelet-activating factor antagonism in endotoxemic man.

  1994cited by this paper
• Platelet-activating factor and phospholipase A2 in patients with septic shock and trauma

  1994cited by this paper
• Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide.

  1993cited by this paper
• NHLBI workshop summary. Platelet-activating factor: role in pulmonary injury and dysfunction and blood abnormalities.

  1992cited by this paper
• Platelet‐activating factor in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome

  1992influential reference
• Involvement of platelet-activating factor (PAF) in septic shock and priming as indicated by the effect of hetrazepinoic PAF antagonists

  1991cited by this paper
• Effect of platelet-activating factor receptor antagonism on endotoxin-induced lung dysfunction in awake sheep.

  1990cited by this paper
• A triazolodiazepine platelet activating factor receptor antagonist (WEB 2086) reduces pulmonary dysfunction during endotoxin shock in swine.

  1990cited by this paper
• Occupancy of platelet receptors for platelet-activating factor in patients with septicemia.

  1989cited by this paper
• Symmetric group sequential test designs.

  1989cited by this paper
• Intravascular release of platelet activating factor in children with sepsis.

  1987cited by this paper
• Platelet-Activating Factor and Related Lipid Mediators

  1987cited by this paper
• APACHE II: A severity of disease classification system

  1985cited by this paper

• Mannose-6-phosphate: a shield for the pulmonary endothelium

  2025cites this paper
• Designed microchannel-based lipid nanoparticles encapsulated siRNA targeting gasdermin D for sepsis management via pulmonary delivery

  2025cites this paper
• The End of “One Size Fits All” Sepsis Therapies: Toward an Individualized Approach

  2022cites this paper
• Chasing the Ghost: Hyperinflammation Does Not Cause Sepsis

  2022cites this paper
• Platelet Activating Factor (PAF): A Mediator of Inflammation

  2022cites this paper
• Activation of Neutrophil Granulocytes by Platelet-Activating Factor Is Impaired During Experimental Sepsis

  2021cites this paper
• The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia

  2021cites this paper
• Phospholipases A2 as biomarkers in acute respiratory distress syndrome

  2021cites this paper
• Signaling pathways and intervention therapies in sepsis

  2021cites this paper
• The lipid biology of sepsis

  2021cites this paper
• Platelet-Activating Factor

  2021cites this paper
• Lipid and Lipoprotein Dysregulation in Sepsis: Clinical and Mechanistic Insights into Chronic Critical Illness

  2021cites this paper
• Adjunctive Immunotherapy With Polyclonal Ig-M Enriched Immunoglobulins for Septic Shock: From Bench to Bedside. The Rationale for a Personalized Treatment Protocol

  2021cites this paper
• Effect of acyl and alkyl analogs of platelet-activating factor on inflammatory signaling.

  2020cites this paper
• Immune Response Resetting as a Novel Strategy to Overcome SARS-CoV-2–Induced Cytokine Storm

  2020cites this paper
• Targeting of G-protein coupled receptors in sepsis.

  2020cites this paper
• Advance in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation

  2019cites this paper
• Elevated Levels of Platelet Activating Factor and Its Acetylhydrolase Indicate High Risk of Kawasaki Disease

  2019cites this paper
• Which Multicenter Randomized Controlled Trials in Critical Care Medicine Have Shown Reduced Mortality? A Systematic Review.

  2019cites this paper
• Personalized pharmacological therapy for ARDS: a light at the end of the tunnel

  2019cites this paper
• Re-Evaluating Biologic Pharmacotherapies That Target the Host Response during Sepsis

  2019cites this paper
• Sepsis Management: Importance of the Pathogen

  2018cites this paper
• Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis

  2018cites this paper
• Urate crystals induce macrophage PAF‑AH secretion which is differentially regulated by TGFβ1 and hydrocortisone.

  2018cites this paper
• ADJunctive Ulinastatin in Sepsis Treatment in China (ADJUST study): study protocol for a randomized controlled trial

  2018cites this paper
• Lipoprotein-associated Phospholipase A 2 in Placenta and Fetus – Effect of Obesity and Gestational Diabetes

  2017cites this paper
• MULTIPLE ORGAN DYSFUNCTION SYNDROME

  2017cites this paper
• Bridging the Translational Gap: The Challenges of Novel Drug Development in Critical Care

  2017cites this paper
• The Treatment of Sepsis: From Failed Therapies to New Possibilities

  2016cites this paper
• Sepsis: in search of cure

  2016cites this paper
• Terrestrial Invertebrate Animal Metagenomics, Lumbricidae

  2015cites this paper
• A Molecular Host Response Assay to Discriminate Between Sepsis and Infection-Negative Systemic Inflammation in Critically Ill Patients: Discovery and Validation in Independent Cohorts

  2015cites this paper
• In fl ammation in Chronic HIV Infection : What Can We Do ?

  2015cites this paper
• Inflammation in Chronic HIV Infection: What Can We Do?

  2015cites this paper
• Chapter 6 – Systemic Inflammatory Response Syndrome

  2015cites this paper
• Platelets in the immune response: Revisiting platelet-activating factor in anaphylaxis.

  2015cites this paper
• Combined inhibition of complement and CD14 in human experimentally induced bacterial inflammation and in porcine sepsis

  2015cites this paper
• Prognostication of Mortality in Critically Ill Patients With Severe Infections.

  2015cites this paper
• Pancreatic stone protein - a possible biomarker of multiorgan failure and mortality in children sepsis.

  2014cites this paper
• Pathophysiological Aspects of Lipoprotein-Associated Phospholipase A 2 : A Brief Overview

  2014cites this paper
• Analysis of Invariant Natural Killer T Cells in Intra-Abdominal Sepsis

  2014cites this paper
• To hydrolyze or not to hydrolyze: the dilemma of platelet-activating factor acetylhydrolase

  2014cites this paper
• Strategies to improve drug development for sepsis

  2014cites this paper
• Two Decades of Mortality Trends Among Patients With Severe Sepsis: A Comparative Meta-Analysis*

  2014cites this paper
• [Clinical role of lipoprotein-associated phospholipase A2].

  2013cites this paper
• Bacterial Clearance Is Improved in Septic Mice by Platelet-Activating Factor-Acetylhydrolase (PAF-AH) Administration

  2013cites this paper
• Septic shock: new pharmacotherapy options or better trial design?

  2013cites this paper
• Lentiviral-mediated RNA interference of lipoprotein-associated phospholipase A2 ameliorates inflammation and atherosclerosis in apolipoprotein E-deficient mice.

  2013cites this paper
• Animal models of sepsis

  2013cites this paper
• Targeting the “Cytokine Storm” for Therapeutic Benefit

  2013cites this paper
• Pancreatic stone protein as an early biomarker predicting mortality in a prospective cohort of patients with sepsis requiring ICU management

  2012cites this paper
• Septischer Kreislaufschock und septische Kardiomyopathie

  2012cites this paper
• The effect of lipoprotein-associated phospholipase A2 deficiency on pulmonary allergic responses in aspergillus fumigatus sensitized mice

  2012cites this paper
• Predicting the Risk of Cardiovascular Disease

  2012cites this paper
• The role of the cannabinoid system in sepsis

  2012cites this paper
• SECTION A: Septicemia,Toxin-andInflammation-MediatedSyndromes PART II Clinical Syndromes and Cardinal Features of Infectious Diseases: Approach to Diagnosis and Initial Management

  2012cites this paper
• Antisense inhibition of secretory and cytosolic phospholipase A2 reduces the mortality in rats with sepsis*

  2012cites this paper
• Antisense inhibition of phospholipase A2: a new approach for already tested therapeutic targets for the treatment of sepsis*.

  2012cites this paper
• A novel platelet-activating factor acetylhydrolase discovered in a metagenome from the earthworm-associated microbial community.

  2011cites this paper
• The individual and unique roles for eosinophils and interleukin-5 in the innate immune response to sepsis

  2011cites this paper
• The systemic mediator-associated response test identifies patients in failed sepsis clinical trials among whom novel drugs reduce mortality.

  2011cites this paper
• Heart Rate as Prognostic Marker and Therapeutic Target In MODS

  2011cites this paper
• Immune-modulating interventions in critically ill septic patients: pharmacological options

  2011cites this paper
• Circulating Platelet-Activating Factor Is Primarily Cleared by Transport, Not Intravascular Hydrolysis by Lipoprotein-Associated Phospholipase A2/ PAF Acetylhydrolase

  2011cites this paper
• The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice

  2011cites this paper
• Inhibition of Lipoprotein-Associated Phospholipase A2 Ameliorates Inflammation and Decreases Atherosclerotic Plaque Formation in ApoE-Deficient Mice

  2011cites this paper
• SIRS, Sepsis und Multiorganversagen

  2011cites this paper
• Decrease of Plasma Platelet-Activating Factor Acetylhydrolase Activity in Lipopolysaccharide Induced Mongolian Gerbil Sepsis Model

  2010cites this paper
• Recent Developments with Lipoprotein-Associated Phospholipase A2 Inhibitors

  2010cites this paper
• The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses.

  2010cites this paper
• OxLDL stimulates lipoprotein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways.

  2010cites this paper
• Are the concepts of SIRS and MODS useful in sepsis

  2010cites this paper
• Factors Influencing the Efficacy of Mediator‐Specific Anti‐Inflammatory, Glucocorticoid, and Anticoagulant Therapies for Sepsis

  2010cites this paper
• Darapladib and its potential for plaque stabilization and prevention of cardiac events

  2010cites this paper
• Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response.

  2009cites this paper
• Chapter 11 – Systemic Inflammatory Response Syndrome

  2009cites this paper
• Better infrastructure: Industry–academia partnerships—A marriage of convenience?

  2009cites this paper
• Serum Activity of Platelet-Activating Factor Acetylhydrolase Is a Potential Clinical Marker for Leptospirosis Pulmonary Hemorrhage

  2009cites this paper
• A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia

  2009cites this paper
• Immunomodulation in the critically ill

  2009cites this paper
• Prevalence and Significance of Coagulation Abnormalities in Community-Acquired Pneumonia

  2009cites this paper
• Improving clinical trials in the critically ill: Unique challenge—Sepsis

  2009cites this paper
• Inter‐individual variability of plasma PAF‐acetylhydrolase activity in ARDS patients and PAFAH genotype

  2009cites this paper
• Better conduct of clinical trials: The control group in critical care trials

  2009cites this paper
• Multicenter, randomized, controlled trials evaluating mortality in intensive care: Doomed to fail?

  2008influential citation
• Science, medicine and industry: are we getting out of the black hole in sepsis research?

  2008cites this paper
• Infectious Diseases in the Pediatric Intensive Care Unit

  2008cites this paper
• Modulation of Lipid and Protein Mediators of Inflammation by Cytosolic Phospholipase A2α during Experimental Sepsis1

  2008cites this paper
• during Experimental Sepsis a 2Aof Inflammation by Cytosolic Phospholipase Modulation of Lipid and Protein Mediators

  2008cites this paper
• Acute lung injury in a rat model of intestinal ischemia-reperfusion: the potential time depended role of phospholipases A(2).

  2008cites this paper
• Entzündung und angeborene Immunantwort

  2008cites this paper
• Multiple Organ Dysfunction Syndrome

  2008cites this paper
• Acute Lung Injury in a Rat Model of Intestinal Ischemia-Reperfusion: The Potential Time Depended Role of Phospholipases A2

  2008cites this paper
• New therapies for sepsis.

  2008cites this paper
• Chapter 26 – Severe Sepsis and Multiple Organ Dysfunction

  2008cites this paper
• Predisposition to Sepsis

  2008cites this paper
• The effect of thawing fresh frozen plasma at various temperatures on in vitro coagulation factor activity

  2008cites this paper
• Health care-associated infection (HAI): a critical appraisal of the emerging threat-proceedings of the HAI Summit.

  2008cites this paper
• The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.

  2008cites this paper
• Multiple Roles of Phospholipase A2 during Lung Infection and Inflammation

  2008influential citation